Improved bioavailability of a water-insoluble drug by inhalation of drug-containing maltosyl-β-cyclodextrin microspheres using a four-fluid nozzle spray drier

AAPS PharmSciTech

Volumn 13, Issue 4, 2012, Pages 1130-1137

  Ozeki, Tetsuya ^a   Kano, Yoshihito ^b   Takahashi, Norimitsu ^b   Tagami, Tatsuaki ^a   Okada, Hiroaki ^b  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

4 fluid nozzle spray drier; inhalation therapy; maltosyl cyclodextrin; microparticles; water insoluble drug

Indexed keywords

BETA CYCLODEXTRIN; CALCIUM CHANNEL BLOCKING AGENT; DRUG CARRIER; MALTOSYL BETA CYCLODEXTRIN; MICROSPHERE; ONO 2921; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD; DRUG BIOAVAILABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; MEMBRANE MICROPARTICLE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING;

ABSORPTION; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; MALE; MALTOSE; MICROSPHERES; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 84871667734     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9826-z     Document Type: Article

References (37)

1. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113-20.
2. Rasenack N, Hartenhauer H, Muller BW. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm. 2003;254(2):137-45.
3. Rasenack N, Muller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res. 2002;19(12):1894-900.
4. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427-40.
5. Nagarwal RC, Kumar R, Dhanawat M, Das N, Pandit JK. Nanocrystal technology in the delivery of poorly soluble drugs: an overview. Curr Drug Deliv. 2011;8(4):398-406.
6. Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399(1-2):129-39.
7. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62(1):3-16.
8. Kenth S, Sylvestre JP, Fuhrmann K, Meunier M, Leroux JC. Fabrication of paclitaxel nanocrystals by femtosecond laser ablation and fragmentation. J Pharm Sci. 2011;100(3):1022-30.
9. Dong Y, Ng WK, Hu J, Shen S, Tan RB. A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs. Int J Pharm. 2010;386(1-2):256-61.
10. Yamamoto H, Hoshina W, Kurashima H, Takeuchi H, Kawashima Y, Yokoyama T, Tsujimoto H. Engineering of poly(DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidised bed granulating system. Adv Powder Tech. 2007;18:2125-228.
11. Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005;25(4-5):427-37.
12. Patomchaiviwat V, Paeratakul O, Kulvanich P. Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process. AAPS PharmSciTech. 2008;9(4):1119-29.
13. Rodrigues M, Li J, Padrela L, Almeida A, Matos H, Azevedo E. Anti-solvent effect in the production of lysozyme nanoparticles by supercritical fluid-assisted atomization processes. J Supercrit Flu. 2009;48(3):253-60.
14. Mizoe T, Beppu S, Ozeki T, Okada H. One-step preparation of drug-containing microparticles to enhance the dissolution and absorption of poorly water-soluble drugs using a 4-fluid nozzle spray drier. J Contr Release. 2007;120(3):205-10.
15. Mizoe T, Ozeki T, Okada H. Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J Contr Release. 2007;122(1):10-5.
16. Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech. 2008;9(3):755-61.
17. Ohashi K, Kabasawa T, Ozeki T, Okada H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Contr Release. 2009;135(1):19-24.
18. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H. Preparation of polymeric submicron particle-containing microparticles using a 4-fluid nozzle spray drier. Pharm Res. 2006;23(1):177-83.
19. Szejtli J, Szente L. Interaction between indometacin and beta-cyclodextrin. Pharmazie. 1981;36(10):694-8.
20. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol. 1976;83(2):367-82.
21. Irie T, Otagiri M, Sunada M, Uekama K, Ohtani Y, Yamada Y, Sugiyama Y. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J Pharmacobiodyn. 1982;5(9):741-4.
22. Holvoet C, Vander Heyden Y, Plaizier-Vercammen J. Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use. Drug Dev Ind Pharm. 2005;31(6):567-75.
23. Rajewski RA, Traiger G, Bresnahan J, Jaberaboansari P, Stella VJ, Thompson DO. Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. J Pharm Sci. 1995;84(8):927-32.
24. Tokihiro K, Arima H, Tajiri S, Irie T, Hirayama F, Uekama K. Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether beta-cyclodextrin in rats. J Pharm Pharmacol. 2000;52(8):911-7.
25. Nishi M, Ishikawa T, Matsumoto Y, Katsube N, Takeishi N, Yonamine H, Matsui T, Okano K, Nakanishi O. Biochemical and physical treatment in rat neuropathic pain and nerve growth factor. Pain Res. 2004;19(4):141-9.
26. Suzuki A, Omori H, Kinoshita M, Akaike A, Satoh M, Kaneko S. A novel analgesic, ONO-2921, cause a use-dependent inhibition of human N-type (.Alpha.1B) Ca2+ channels and increases inactivated state. Jpn J Pharmacol. 2002;88(1):162.
27. Komada F, Iwakawa S, Yamamoto N, Sakakibara H, Okumura K. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J Pharm Sci. 1994;83(6):863-7.
28. Weibel ER, Gil J. Structure-function relationship at the alveolar level. In: West JB, editor. Bioengineering Aspects of the Lung. New York: Marcel Dekker; 1977. p. 1-81.
29. Watanabe M, Ozeki T, Shibata T, Murakoshi H, Takashima Y, Yuasa H, Okada H. Effect of shape of sodium salicylate particles on physical property and in vitro aerosol performance of granules prepared by pressure swing granulation method. AAPS PharmSciTech. 2003;4(4):E64.
30. European Pharmacopoeia. Section 2.9.18 preparations for inhalation: aerodynamic assessment of fine particles. In EP. 3rd ed. Strasbourg: Council of Europe; 2001.
31. United States Pharmacopoeia. Chapter 601. Physical tests and determinations: aerosols. 2003. p. 2105-23.
32. Podczrck P. Optimization of the operation conditions of an Andersen-Cascade impactor and the relationship to centrifugal adhension measurements to aid the development of dry powder inhalations. Int J Pharm. 1997;149:51-61.
33. Higuchi T, Conners K. Advance in analytical chemistry and instrumentation. New York: CN Reilly Interscience; 1965.
34. Newman SP, Hollingsworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm. 1994;102:127-32.
35. Vidgren M, Karkkainen A, Karjalainen P, Paronen P, Nuutinen J. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm. 1988;42:211-6.
36. Okimoto K, Miyake M, Ohnishi N, Rajewski RA, Stella VJ, Irie T, Uekama K. Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE)7 m-beta-CD. Pharm Res. 1998;15(10):1562-8.
37. Okimoto K, Rajewski RA, Stella VJ. Release of testosterone from an osmotic pump tablet utilizing (SBE)7 m-beta-cyclodextrin as both a solubilizing and an osmotic pump agent. J Contr Release. 1999;58(1):29-38.